Cytek Biosciences, Inc.CTKB财报
Nasdaq · 医疗保健 · 实验室分析仪器
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.10% | 17.8M | ▲ +2.20pp | 2024-01-23 |
| The Vanguard Group | 8.77% | 11.9M | — | 2024-02-13 |
| NOS. OF ABOVE PERSONS | 7.22% | 9.5M | ▲ +2.02pp | 2024-11-14 |
| Hillhouse Investment Management, Ltd. | 5.10% | 6.7M | — | 2024-11-14 |
| RA Capital Management, L.P. | 4.99% | 6.8M | — | 2023-09-19 |
| HHLR Advisors, Ltd. | 4.90% | 6.7M | — | 2024-02-14 |
| Ming Yan | 4.70% | 6.2M | — | 2024-02-14 |
| Wenbin Jiang | 4.30% | 5.7M | — | 2024-02-14 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-03-13 | Ming Yan | CHIEF TECHNOLOGY OFFICER | Gift | 1.18M | $0.00 | $0 |
| 2026-03-10 | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Option exercise | 2.0K | — | — |
| 2026-03-10 | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Option exercise | 2.9K | — | — |
| 2026-03-10 | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Option exercise | 4.8K | — | — |
| 2026-03-10 | McCombe William D. | Chief Financial Officer | Option exercise | 6.3K | — | — |
| 2026-03-10 | McCombe William D. | Chief Financial Officer | Option exercise | 17.4K | — | — |
| 2026-03-10 | Wenbin Jiang | PRESIDENT AND CEO | Option exercise | 15.7K | — | — |
| 2026-03-10 | Wenbin Jiang | PRESIDENT AND CEO | Option exercise | 29.5K | — | — |
| 2026-03-10 | Wenbin Jiang | PRESIDENT AND CEO | Option exercise | 38.7K | — | — |
| 2026-03-10 | Valerie Barnett | CHIEF LEGAL OFFICER | Option exercise | 4.9K | — | — |
1–10 of 20
第 1 页 / 共 2 页